The submission was primarily based on updated phase II efficacy and safety data for tazemetostat for patients with relapsed or refractory follicular lymphoma who have received at least 2 prior lines of systemic therapy.
Bristol-Meyers Squibb Company announced that the FDA granted a priority review to its BLA for liso-cel to treat patients with relapsed or refractory large B-cell lymphoma.
Researchers found that targeting BCL-W in Burkitt lymphoma and diffuse large B-cell lymphoma may not offer wide-ranging therapeutic benefit.
Patients with either relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with CAR NK cells had a response without the development of cytokine release syndrome, neurotoxicity, or graft-versus-host disease.
Calibr received approval from the FDA to move forward with an investigational new drug to treat relapsed/refractory B-cell malignancies with a switchable CAR T-cell therapy.
Researchers indicated that a lack of understanding of the mechanism and efficacy of PD-1/PD-L1 inhibitors is the major barrier for prescription of these inhibitors in Chinese tumor treatment-related departments.
The associate professor at The Ohio State University Comprehensive Cancer Center explained the goals for the future of the CAR T-cell therapy data in patients with DLBCL.
The medical oncologist from the John Theurer Cancer Center noted the importance of real-world data in determining potentially different toxicity profiles in these BTK-inhibitors.
Though physical activity guidelines are largely based on chronic diseases like cardiovascular disease and diabetes, these data suggest they are important to cancer prevention as well.
Diego Villa, MD, FRCPC, elaborated on the progress made with bendamustine and rituximab as induction therapy for transplant eligible and ineligible patients with mantle cell lymphoma.